Biotechnology atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression – ATAI Life Sciences (NASDAQ:ATAI) Read more
Biotechnology Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy – Ocugen (NASDAQ:OCGN) Read more
Biotechnology Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410 – Ocugen (NASDAQ:OCGN) Read more
Biotechnology FDA Approves Johnson & Johnson’s Reduced Tecvayli Dosing In Pretreated Multiple Myeloma Patients – Johnson & Johnson (NYSE:JNJ) Read more
Biotechnology Sarepta Therapeutics’ Next-Gen Duchenne Muscular Therapy Shows Efficacy At Less Frequent Dosing – Sarepta Therapeutics (NASDAQ:SRPT) Read more